RPRX FY2025 SEC EDGAR DEF 14A #160 of 168 in industry

Royalty Pharma plc CEO pay ratio

The CEO earned $350K in FY2025 against median worker pay of $349,893 · Chemicals & Pharmaceuticals.

Chemicals & Pharmaceuticals peers All rankings
State
X0
Filing date
2026-04-10
Industry
Chemicals & Pharmaceuticals
Industry rank
#160/168

Data updated August 2026

Subscribe to Royalty Pharma plc CEO pay filing updates (RSS)

CEO-to-worker pay ratio
4:1
Below Average (Scale: 0–1000:1)
CEO pay
$350K
Median worker
$349,893

Answer first

Royalty Pharma plc's FY2025 CEO total of $350K ranks #1298 of 1,423 complete filings; its 4:1 pay ratio ranks #1372. Dollar rank is not ratio rank.

According to the same FY2025 complete-filing cohort used on the rankings boards (CEO total, median worker, and ratio all present). Median worker pay is $349,893. Industry placement uses the FY2025 SIC-28 peer cohort (# 160 of 168, 5th percentile - among the lower quartile of industry peers by pay ratio). Figures come from Section 953(b) Dodd-Frank DEF 14A disclosures - not estimates. View all Chemicals & Pharmaceuticals companies.

Dollar rank
#1298
$350K of 1,423 FY2025
Ratio rank
#1372
4:1 of 1,423
Industry pct
5th
among the lower quartile of industry peers by pay ratio

How Royalty Pharma plc ranks nationally

Royalty Pharma plc CEO pay vs. every FY2025 complete filing

Total CEO compensation, the full national distribution, this company marked

$349,893 9th percentile higher than 9% of 1,423 companies

$0–$2,500,000: 304 companies (21%). This entry sits in this band. $2,500,000–$5,000,000: 182 companies (13%). Above this entry. $5,000,000–$7,500,000: 208 companies (15%). Above this entry. $7,500,000–$10,000,000: 192 companies (13%). Above this entry. $10,000,000–$12,500,000: 139 companies (10%). Above this entry. $12,500,000–$15,000,000: 91 companies (6%). Above this entry. $15,000,000–$17,500,000: 88 companies (6%). Above this entry. $17,500,000–$20,000,000: 54 companies (4%). Above this entry. $20,000,000–$22,500,000: 24 companies (2%). Above this entry. $22,500,000–$25,000,000: 34 companies (2%). Above this entry. $25,000,000–$27,500,000: 24 companies (2%). Above this entry. $27,500,000–$30,000,000: 16 companies (1%). Above this entry. $30,000,000–$32,500,000: 10 companies (1%). Above this entry. $32,500,000–$35,000,000: 7 companies (0%). Above this entry. $35,000,000–$37,500,000: 9 companies (1%). Above this entry. $37,500,000–$40,000,000: 6 companies (0%). Above this entry. $40,000,000–$42,500,000: 1 companies (0%). Above this entry. $42,500,000–$45,000,000: 1 companies (0%). Above this entry. $45,000,000–$47,500,000: 6 companies (0%). Above this entry. $47,500,000–$50,000,000: 27 companies (2%). Above this entry. This company $0 $50M+ every complete-filing company, bucketed by value

Each bar is a $2500K-wide band; taller bars hold more companies. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source SEC DEF 14A Section 953(b) disclosures, PlainCEOPay extract · FY2025

Royalty Pharma plc vs. Chemicals & Pharmaceuticals peers

CEO total pay ($350K) against pay ratio (4:1) for Royalty Pharma plc (marked) and its 5 closest same-industry peers, against the Chemicals & Pharmaceuticals industry median on both axes.

Pay + gap both highContained pay, wide gapHigh pay, contained gapBelow peer norms on both02069254.34138508.56207762.88277017.11.0:111.8:122.5:133.2:144.0:1CEO total payPay ratio (CEO : median worker)Royalty Pharma plc, CEO total pay: 349893 · Pay ratio (CEO : median worker): 4:1Royalty Pharma plcHighwater Ethanol LLC, CEO total pay: 394644 · Pay ratio (CEO : median worker): 4:1Highwater Ethanol LLCViridian Therapeutics, Inc.\DE, CEO total pay: 6776249 · Pay ratio (CEO : median worker): 4:1Viridian Therapeutics, Inc.\DEREX AMERICAN RESOURCES Corp, CEO total pay: 5275200 · Pay ratio (CEO : median worker): 4:1REX AMERICAN RESOURCES CorpCelanese Corp, CEO total pay: 462700 · Pay ratio (CEO : median worker): 5:1Celanese CorpSummit Therapeutics Inc., CEO total pay: 1025895 · Pay ratio (CEO : median worker): 3:1Summit Therapeutics Inc.
Royalty Pharma plc vs. Chemicals & Pharmaceuticals peers, plotted against the industry's $7.9M median CEO total and 42:1 median pay ratio.

Ratio bands among Chemicals & Pharmaceuticals peers

Exclusive CEO-to-median-worker bands across 153 complete latest-FY filings in SIC 28. Segments sum to the peer set, not this company's compensation pillar.

CEO Compensation Breakdown, FY2025

A component-level pay breakdown is not reported in Royalty Pharma plc's structured SEC pay-ratio disclosure. See our methodology →

Filing-year trail · Royalty Pharma plc

Complete DEF 14A pay-ratio filings for this CIK across FY2021–2025. Year-over-year deltas compare adjacent filing years only; incomplete dollar rows are omitted (same completeness gate as the hero figures).

Latest ratio
4:1
FY2025
vs prior FY
-236:1
from FY2023 240:1
CEO $ YoY
-0.9%
$350K latest
Filings shown
4
FY2021–2025
Royalty Pharma plc CEO total compensation, median worker pay, and pay ratio by fiscal year from SEC EDGAR DEF 14A.
FY CEO pay Δ pay Median worker Pay ratio Δ ratio
2021 $374K - $373,719 132:1 -
2022 $337K -9.8% $337,085 277:1 +145:1
2023 $353K +4.7% $353,061 240:1 -37:1
2025 $350K -0.9% $349,893 4:1 -236:1

Source: SEC EDGAR DEF 14A pay-ratio disclosures for CIK 1802768, FY2021–2025. Adjacent-year deltas only.

Industry Comparison - Chemicals & Pharmaceuticals

This Company's Ratio
4:1
Industry Median Ratio
42:1
Industry Median CEO Pay
$7.9M
This CEO's Pay
$350K
Companies in Industry
168
vs. Industry Median
Below
#160 of 168 by pay ratio in this industry View all companies in Chemicals & Pharmaceuticals →

Royalty Pharma plc: near-parity Item 402(u) ratio

Royalty Pharma plc's FY2025 ratio 4:1 ranks #160 of 168 Chemicals & Pharmaceuticals filers (5th percentile). the CEO earned 4× the median employee ($349,893) in FY2025.

At $349,893 median worker pay, the FLOOR stamp is near pay-parity territory under MICRO CEO total.

CEO Total Pay

$350K

FY2025 Summary Compensation, below median

Pay Ratio

4:1

Below typical

Royalty Pharma plc in the lower Chemicals & Pharmaceuticals third

Royalty Pharma plc's FY2025 ratio 4:1 ranks #160 of 168 Chemicals & Pharmaceuticals filers (5th percentile). The structured pay-ratio disclosure reports the total without line-item components. Chemicals & Pharmaceuticals (SIC 28) median ratio is 42:1 across 168 FY2025 filers; Royalty Pharma plc's $350K CEO total is at or below the $7.9M industry median CEO pay.

Dollar rank #1298 and ratio rank #1372 split - treat 4:1 as a disclosure, not a fairness score. Open Chemicals & Pharmaceuticals peers.

Key Data, FY2025

Total Compensation
$350K
Median Employee Pay
$349,893
Pay Ratio
4:1
Filing Date
2026-04-10

Company Info

Ticker
RPRX
CIK
1802768
Industry
Chemicals & Pharmaceuticals
SIC Code
2834
State
X0
View SEC filings →
SEC EDGAR DEF 14A for CIK 1802768, FY2025. Informational only, not investment advice. Verify on EDGAR.

Read our methodology - how this data is sourced, computed, and verified. Royalty Pharma plc's FY2025 ratio 4:1 ranks #160 of 168 Chemicals & Pharmaceuticals filers (5th percentile).

Read with Royalty Pharma plc

ABS(ceo_total_comp) peers first, then a SIC pole and a stamp-branched guide - not a fixed Related strip. This page stamps FLOOR · MICRO · ELITE-MED.

WillScot Holdings Corp · MICRO

ABS(ceo_total_comp) peer at $350K (Δ $73 lighter vs Royalty Pharma plc); FLOOR · PAR-MED vs this page's FLOOR · MICRO · ELITE-MED.
Horizon Bancorp Inc /in/ · MICRO

ABS(ceo_total_comp) peer at $356K (Δ $6K heavier vs Royalty Pharma plc); FLOOR · PAR-MED vs this page's FLOOR · MICRO · ELITE-MED.
BrightSpire Capital, Inc. · MICRO

ABS(ceo_total_comp) peer at $363K (Δ $13K heavier vs Royalty Pharma plc); FLOOR · ELITE-MED vs this page's FLOOR · MICRO · ELITE-MED.
Markel Group Inc. · MICRO

ABS(ceo_total_comp) peer at $364K (Δ $14K heavier vs Royalty Pharma plc); FLOOR · HIGH-MED vs this page's FLOOR · MICRO · ELITE-MED.
Highwater Ethanol LLC (SIC 28 pole)

Highwater Ethanol LLC stamps FLOOR · MICRO nearest in-SIC by ABS(pay_ratio) to Royalty Pharma plc's FLOOR filing.
National dual ranks · #1298/#1372

Royalty Pharma plc's FY2025 package sits #1298 by CEO dollars and #1372 by ratio under MICRO · FLOOR.
Ratio primer · FLOOR

Royalty Pharma plc's FLOOR stamp sits in the lower Item 402(u) band - start with how the ratio is disclosed before comparing peers.
Data sourced from SEC EDGAR DEF 14A for Royalty Pharma plc (CIK 1802768), FY2025. See our methodology. Aggregated by PlainCEOPay as of August 2026.

Data currency: Executive compensation from SEC EDGAR DEF 14A proxy statements through fiscal year 2025, compiled and last refreshed August 2026. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.